The changing glaucoma treatment paradigm
- PMID: 35174602
- DOI: 10.1111/ceo.14052
The changing glaucoma treatment paradigm
References
REFERENCES
-
- GBD 2019 Blindness and Vision Impairment Collaborators Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study. Lancet Global Health. 2020;9(2):e144-e160.
-
- Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology. 2014;121(11):2081-2090.
-
- Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet Lond Engl. 2014;385(9975):1295-1304.
-
- Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression. Arch Ophthalmol. 2002;120(10):1268.
-
- Newman-Casey PA, Robin AL, Blachley T, et al. The Most common barriers to glaucoma medication adherence a cross-sectional survey. Ophthalmology. 2015;122(7):1308-1316.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
